454 results about "Oral solutions" patented technology

The invention relates to the technical field of pharmaceutical preparations, in particular to an upatinib oral solution as well as a preparation method and application thereof. The oral upatinib solution is prepared from the following components in percentage by weight: 0.1%-1.5% of upatinib, 1%-20% of hydroxypropyl beta-cyclodextrin, 0.5%-5% of a flavoring agent and the balance of water, wherein the oral upatinib solution is prepared from the following components in percentage by weight: 0.1%-1.5% of upatinib, 1%-20% of hydroxypropyl beta-cyclodextrin, 0.5%-5% of a flavoring agent and the balance of water; the degree of substitution of the hydroxypropyl beta-cyclodextrin is 4.0 to 5.5. The oral upatinib solution overcomes the problems of overlarge tablet diameter, poor oral compliance, low solubility in water and low bioavailability of upatinib tablets in the prior art, and has the advantages of simplicity in preparation and convenience in use.

The present invention relates to a cannabinoid containing oral solution. Preferably the oral solution comprises a cannabinoid, a lipid solvent, a sweetener and ethanol, characterised in that the sweetener is an ultrahigh potency sweetener.

The present invention provides a hydrangea oral liquid and a preparation method thereof, and relates to the field of biological fermentation technology. The preparation method of the hydrangea oral liquid of the present invention comprises: crushing the dried hydrangea fruiting bodies, mixing with glucose and water, ultrasonic treatment, obtaining a mixed material, inoculating a composite bacterial agent for fermentation, adding a composite enzyme for enzymolysis, filtering and concentrating, and obtaining the hydrangea oral liquid. The present invention combines hydrangea crushing with ultrasound, improves the dissolution of nutrients in hydrangea, and shortens the fermentation time; the composite bacterial agent fermentation can significantly increase the polysaccharide substances in the hydrangea oral liquid, and enhances the antioxidant effect; the composite bacterial agent fermentation of hydrangea and the composite enzyme enzymolysis can significantly improve the mushroom smell caused by the hydrangea itself. The experimental results show that the hydrangea oral liquid prepared by the method of the present invention can improve the mushroom smell caused by hydrangea, increase the polysaccharide content, and enhance the antioxidant performance.

The invention relates to the technical field of pharmaceutical analysis, in particular to a method for detecting related substances of a compound sodium picosulfate oral solution. According to the method, high performance liquid chromatography is adopted for detection, a chromatographic column is a bonded silica gel reversed-phase chromatographic column, a mobile phase A is a dipotassium phosphate buffer solution, a mobile phase B is acetonitrile, and gradient elution is adopted. The method can effectively detect related substances in the compound sodium picosulfate oral solution, has the advantages of strong specificity, high sensitivity and the like, has good detection capability on specific impurities in the compound sodium picosulfate oral solution, and effectively guarantees the quality of the compound sodium picosulfate oral solution.

The invention provides an oral cavity soluble film solution based on a nano-carrier and a preparation method of an oral cavity soluble film. According to the method, a nano-carrier technology, microcapsule multilayer coating, a low-temperature electrochemical polymerization method and an ultrasonic dispersion technology are utilized, and uniform distribution and multi-stage slow release of a medicine in an oral instant film are achieved. According to the invention, active pharmaceutical ingredients are firstly wrapped by a nano-carrier, and then a multi-layer composite coating structure is formed by a microcapsule technology, so that drug release effects at different stages are realized. And then, uniformly mixing the microcapsule nano-drug particles with a film-forming substrate, depositing layer by layer to form a film through a low-temperature electrochemical polymerization method, and carrying out low-temperature drying treatment. The soluble film disclosed by the invention has good biocompatibility and mechanical strength, and can be gradually dissolved in an oral cavity, and the medicine is released according to a set stage, so that a long-acting oral care or treatment effect is realized. The method avoids the use of high temperature and organic solvents, is environment-friendly and safe, and is suitable for delivery systems of various oral drugs.

The invention discloses a quality control method based on a levocarnitine oral solution preparation process, and relates to the technical field of quality detection. The quality control method based on the preparation process of the levocarnitine oral solution comprises the following steps: acquiring oral solution monitoring data; evaluating oral liquid quality; feeding back a result; and optimizing quality control parameters. According to the method, oral liquid quality evaluation is carried out through the obtained oral liquid monitoring data, the process quality feedback data is obtained, then the process parameter algorithm model is constructed according to the process quality feedback data, result feedback is carried out, and finally whether quality control parameter optimization is carried out or not is judged based on the process parameter algorithm model. The effect of improving the character stability of the prepared levocarnitine oral solution is achieved, and the problem that in the prior art, the quality of the prepared levocarnitine oral solution is difficult to control is solved.

The invention discloses a CAD detection method for phosphoric acid and phosphorous acid in an alendronate sodium oral solution, and belongs to the technical field of pharmaceutical analysis. The method comprises the following steps: preparing a reference stock solution and a test solution; then setting high performance liquid chromatography detection conditions; a Shodex VN-504D chromatographic column is adopted, a CAD detector is adopted as a detector, a mixed solution of a mobile phase A and a mobile phase B is adopted as a mobile phase, the mobile phase A is ammonium formate, the mobile phase B is an acetonitrile solution, and gradient elution is performed by adopting the mobile phase; and respectively measuring the reference stock solution and the test solution, injecting into a liquid chromatograph, and recording a chromatogram. A CAD detector is adopted, the detection sensitivity is obviously improved, the quantitative concentration can reach 0.24 mu g / mL, and the detection concentration can reach 0.10 mu g / mL. The method is high in specificity, high in sensitivity, good in durability, rapid, simple, effective and reliable.

The invention provides a detection method for related substances in loxoprofen sodium oral solution. The adopted ternary mobile phase system solves the interference of auxiliary materials in the low absorption band on the detection of known impurities, thereby avoiding the problem of missed detection and insufficient detection of impurities, effectively solving the interference of auxiliary material methylparaben on the detection of impurities when the related substances are determined, and the types and numbers of impurities to be monitored are large, the separation between various impurities, between impurities and main components, and between impurities and auxiliary materials is good, the related substances in the loxoprofen sodium oral solution can be quickly and accurately monitored, and the method has important significance for the quality evaluation of the loxoprofen sodium oral solution.

The invention relates to an ambroxol hydrochloride oral solution which is prepared from the following raw and auxiliary materials in parts by weight: 0.3-0.6 part of ambroxol hydrochloride; 0.04 to 0.06 part by weight of benzoic acid; 0.3 to 0.6 part by weight of hydroxyethyl cellulose; 0.08 to 0.2 part by weight of sucralose; 0.15 to 0.4 part by weight of essence; and the balance of purified water. The preparation method comprises the following steps: S1, adding a base solution; S2, adding ingredients; and S3, filtering. The preparation method comprises the following steps: S1, hydroxyethyl cellulose pretreatment; S2, mixing; S3, seasoning; and S4, packaging. The invention provides an ambroxol hydrochloride oral solution and a preparation method thereof. The ambroxol hydrochloride oral solution is good in taste, high in stability and high in patient compliance. And the production process is simple, stable, controllable and easy to industrialize.

The invention belongs to the technical field of analysis and detection of medicine related components, and particularly relates to a method for determining related substances of a methotrexate oral solution, the related substances comprise methotrexate impurity B, impurity C, impurity E, impurity D, impurity H and impurity I. The determination method adopts a high performance liquid chromatography method. A mobile phase of the high performance liquid chromatography comprises a mobile phase A and a mobile phase B, the mobile phase A is a buffer salt solution, the mobile phase B is acetonitrile, and gradient elution is adopted. According to the method, a plurality of known impurities in the methotrexate oral solution can be measured at the same time by utilizing the high performance liquid chromatography, interference generated by a blank solvent and an auxiliary material solution is eliminated, and the method can be used for accurately and quantitatively detecting related substances in the preparation process and the storage process of the methotrexate oral solution and serves as an important component for medicine quality control. The clinical use risk is reduced. The method is good in specificity, good in separation degree, good in accuracy and high in practicability in actual quality control work.

The invention belongs to the technical field of health-care products, and provides nano donkey-hide gelatin oral liquid and a preparation method thereof. The preparation method comprises the following steps: S1, crushing colla corii asini, mixing the crushed colla corii asini with a surfactant solution, and performing ultrasonic treatment to obtain coated colla corii asini particles; s2, mixing jujubes, Chinese wolfberry fruits and haws, crushing to obtain a mixture, mixing the mixture, the coated donkey-hide gelatin particles and water, and extracting to obtain an extracting solution; s3, concentrating the extracting solution to obtain a concentrated solution; s4, mixing the concentrated solution, psicose and astaxanthin, and performing nanoscale homogenization treatment to obtain the nano donkey-hide gelatin oral liquid. A layer of protective film is formed on the surface of the donkey-hide gelatin fine powder through a surface modification technology, so that the agglomeration phenomenon of the donkey-hide gelatin in the extraction process is effectively prevented. The donkey-hide gelatin particles are further refined through high-pressure homogenization treatment, so that the donkey-hide gelatin particles reach the nanoscale, and the solubility and bioavailability of the donkey-hide gelatin are remarkably improved.

The invention discloses an oral solution analysis and detection device and a method thereof, and relates to the technical field of oral solution analysis and detection, the oral solution analysis and detection device comprises a base, the bottom end of a supporting connecting plate is provided with a drawing liquid extraction piece connected with a detection cylinder, and the top of the supporting connecting plate is provided with a locking control piece located on the outer side of the bottom of a second connecting pipe. According to the oral liquid detection device disclosed by the invention, the connection part of a first connecting pipe and a second connecting pipe is shielded by arranging a drawing liquid extraction piece, upwards pushing a pushing insertion rod and rotating the pushing insertion rod, and meanwhile, a third piston rod moves downwards relative to a detection cylinder, so that oral liquid in a liquid storage bin is equally divided; the first piston rod is pushed and the first liquid storage bin is rotated, so that the detection agent can enter the detection cylinder, the same amount of oral liquid in the detection cylinder is in contact with different detection agents, the reaction of the oral liquid after being fully mixed with other elements is rapidly detected, and the detection efficiency is improved.

The present invention refers to pharmaceutical compositions comprising ibuprofen or a pharmaceutically acceptable derivative thereof and one or more solubilizing agents in the form of A) aqueous solution for use in intravenous administration comprising ibuprofen of either the sodium or lysinate salt, paracetamol and preferably one or more cyclodextrins or B) aqueous solution for use in intravenous administration wherein the one or more solubilizing agents are one or more essential amino acids and optionally one or more cyclodextrins or C) composition for use in oral administration, which comprises paracetamol and cyclodextrin, wherein said composition is in the form of either i) effervescent tablets or effervescent granules or ii) oral suspension or syrup or oral solution or iii) soft capsules.

The invention discloses an ebastine oral solution preparation method, which comprises: 1, weighing 5-20 parts by mass of ebastine, 50-100 parts by mass of a thickening agent, 10-18 parts by mass of a bacteriostatic agent, 1800-2000 parts by mass of a thickening agent, 0.1-0.2 part by mass of a defoaming agent, 600-700 parts by mass of a sweetening agent, adjusting the pH value to 3.5-4.5 by using a pH value adjusting agent, and carrying out a proper amount of water; 2, adjusting the temperature to 35 DEG C, adding ebastine into the thickening agent, and stirring to completely disperse the ebastine; 3, adding part of purified water, an acidity regulator and a thickening agent, and stirring until the materials are completely dissolved; 4, adding the sweetening agent, the bacteriostatic agent and the defoaming agent, and stirring until the materials are completely dissolved; 5, cooling after complete dissolution, and adjusting the pH value to 4 by using an alkaline regulator; step 6, fixing the volume; by optimizing the preparation process, efficient dissolution of the ebastine oral solution is realized, the problems of clinical application pain points of tablets and low solubility of raw material medicines of the oral solution are solved, and a safer and more convenient treatment choice is provided for special crowds.

The invention discloses a levocarnitine oral solution batch filling device, which relates to the technical field of filling, and comprises a mounting frame, and clamping correction pieces are arranged on the two sides of a second connecting plate. According to the device, through the arrangement of a clamping correction piece, when a third connecting plate moves downwards by a certain distance relative to a second connecting plate, a second piston rod extrudes an aqueous solution in a first side connecting sleeve, so that a movable rack drives a V-shaped correction clamping plate to swing by shifting a first transmission straight gear; the V-shaped correction clamping plate is rotated to be flush with a second connecting plate along with downward movement of a third connecting plate, so that the V-shaped correction clamping plate is buckled on the outer wall of the oral liquid bottle, the oral liquid bottle is corrected, the center of the oral liquid bottle is aligned with the center of an extension pipe, and the accuracy of the extension pipe inserted into the oral liquid bottle is improved; therefore, the extension pipe is prevented from being in contact with the oral liquid bottle, and meanwhile, the situation that the stability of the oral liquid bottle is affected due to uneven stress in the bottle when the oral liquid is injected is also prevented.

The invention belongs to the technical field of medicines, and provides a calcium zinc gluconate oral solution and a preparation method thereof. According to the invention, the sugar alcohol chelating agent is added into the calcium zinc gluconate oral solution, so that the effects of chelating and surface activity can be exerted at the same time, and the higher absorption and mobility of sugar alcohol can be utilized to drive calcium and zinc elements to be better absorbed. Preferably, sorbitol can form a sorbitol calcium ion chelate and a sorbitol zinc ion chelate with calcium ions in calcium gluconate and zinc ions in zinc gluconate, so that the stability and water solubility of the sorbitol calcium ion chelate and the sorbitol zinc ion chelate are improved, and precipitation of grape calcium carbonate and zinc gluconate is avoided; further, the solubility and the stability of the calcium gluconate and the zinc gluconate in the solution are improved. In addition, after the sorbitol is added, the low-temperature (2-8 DEG C) precipitation of the calcium gluconate is greatly improved. In addition, sorbitol has a fresh and sweet taste, so that the calcium zinc gluconate oral liquid has a good taste.

The invention relates to the technical field of medical preparations, in particular to a preparation method of an atomoxetine hydrochloride oral solution. The atomoxetine hydrochloride oral solution disclosed by the invention is prepared from the following raw materials in parts by weight: 5 to 15 parts of atomoxetine hydrochloride inclusion compound, 0.3 to 0.5 part of sodium benzoate, 16 to 17 parts of sorbitol, 165 to 170 parts of xylitol, 5 to 10 parts of sucralose, 1 to 2 parts of raspberry essence and 300 to 350 parts of deionized water. The atomoxetine hydrochloride oral solution disclosed by the invention has the advantages that in a taste experiment, the atomoxetine hydrochloride oral solution has obvious sweet taste and is well received by testers, the bitter taste of atomoxetine hydrochloride does not exist after the atomoxetine hydrochloride oral solution is eaten, and most importantly, after an acceleration experiment, the atomoxetine hydrochloride oral solution still has good taste and stability.

The invention discloses a mobile phase suitable for simultaneous detection of ambroxol hydrochloride and / or clenbuterol hydrochloride by high performance liquid chromatography. The mobile phase is a mixed solution composed of sodium sulfosuccinate dioctyl ester methanol, water and acetic acid, wherein the mass fraction of the sodium sulfosuccinate dioctyl ester methanol is 0.3%-0.8%; the volume ratio of the sodium sulfosuccinate dioctyl ester methanol with the mass fraction of 0.3%-0.8% to the water to the acetic acid is (740-760): (240-260): 10; the pH value of the mixed solution is 2.8 to 3.2. According to the present invention, the mobile phase is combined with the high performance liquid chromatography to detect the ambroxol hydrochloride oral solution, such that the ambroxol hydrochloride and the clenbuterol hydrochloride can be simultaneously detected, the ambroxol hydrochloride and the clenbuterol hydrochloride can be effectively separated from other impurity peaks, the peak appearance time of the ambroxol hydrochloride can be significantly reduced, and the service life of the chromatographic column can be effectively prolonged.

The invention discloses an iron protein succinate solid dispersion and a preparation method thereof, and belongs to the technical field of medicines. The solid dispersion is prepared from iron protein succinate and a solid dispersion matrix, wherein the solid dispersion matrix is polyethylene glycol or hydroxyethyl starch. The solid dispersion provided by the invention only adopts the iron protein succinate and the solid dispersion matrix as raw materials, and by adjusting the ratio of the iron protein succinate to the solid dispersion matrix, the dispersion has the following advantages: no preservative is added; few types of safe auxiliary materials are used in the prescription; the preparation is formed into a soluble solid form and is convenient to take and carry; the requirements on safety and compliance of pregnant women and infants are met; the adverse reaction of constipation caused by an iron supplement is reduced; the preparation method is easy to implement. The solid dispersion provided by the invention also has the characteristics of no obvious rust flavor and no irritation to the mouth and the tongue; the stability of the dispersoid and the stability of particles prepared from the dispersoid are equivalent to those of commercially available iron protein succinate oral solutions.

The invention provides a dexketoprofen trometamol oral solution and a preparation method thereof. According to the dexketoprofen trometamol oral solution, polyethylene glycol 400 and hydroxypropyl methylcellulose are used as stabilizing agents, methylparaben and propyl hydroxybenzoate are used as bacteriostatic agents, sucralose and ammonium glycyrrhizinate are used as sweetening agents, essence is used as a flavoring agent, and the pH value of the solution is controlled to be 6.2-6.8 through a pH value regulator. The increase of the impurity A, the impurity B, the impurity C, the impurity E and the total impurity is obviously reduced, so that the product stability is obviously improved.

The invention discloses a method for determining impurities in a desloratadine oral solution, the impurities comprise a desloratadine impurity 1, the determination method adopts a high performance liquid chromatography, and the detection conditions of the high performance liquid chromatography are as follows: a chromatographic column is an octyl silane bonded silica gel column or an efficiency equivalent column; the detection wavelength is 254 + / -2nm; the detector is an ultraviolet detector; the column temperature is 35-45 DEG C; the flow rate is 1.1 to 1.3 mL / min; mobile phases: a dipotassium phosphate buffer solution, methanol and acetonitrile; the elution mode is isocratic elution. The determination method disclosed by the invention is good in specificity, good in separation degree, high in sensitivity and good in accuracy, can fully meet the requirements of impurity determination, has important meanings for evaluating the quality of raw material medicines and the advantages and disadvantages of a preparation process, controlling the quality of a final product and detecting a stable sample, and is high in practicability in actual quality control work.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

The invention provides an isoniazide oral solution and a preparation method thereof. According to the isoniazide oral solution, the degradation rate of the product is obviously reduced by controlling the pH value of the finished product to be 5.4-5.9 and the dissolved oxygen to be less than 1mg / L, so that the stability of the product is improved.

The utility model relates to the technical field of oral solution filling, in particular to an oral solution filling device which is characterized in that an upper plate is mounted on the circumferential wall of a base through a connecting frame, a filling structure is mounted on the upper plate and comprises a box body, and a sealing structure for controlling filling is arranged on the circumferential wall of the box body; the sealing blocking plug is in contact with the through hole through the conical surface, a spring is installed between the sealing blocking plug and the box body, it can be guaranteed that the sealing blocking plug is in contact with the through hole through the spring, when the sealing blocking plug bears external pressure, the inner cavity of the box body is communicated with the outside through the through hole, and when the pressure is removed, the sealing blocking plug recovers to the state of sealing the box body again under the thrust of the spring; the sleeve is communicated with the inner cavity of the box body only through the ventilation pipe, the ventilation pipe is vertically arranged upwards, the end, away from the sleeve, of the ventilation pipe is close to the upper wall of the box body, when the sealing blocking plug is pushed to communicate the inner cavity of the box body with the outside, the ventilation position is close to the top face of the box body, and therefore the oral solution is prevented from flowing out of the through hole.

The invention relates to the technical field of pharmaceutical analysis, in particular to a detection method of a compound sodium picosulfate oral solution, which is used for detecting sodium picosulfate and related substances. The detection method comprises the following steps: carrying out liquid chromatography detection on the compound sodium picosulfate oral solution; the conditions of the liquid chromatography detection are as follows: (1) a chromatographic column is a reverse C18 chromatographic column or an efficiency equivalent column thereof; (2) taking a mixed solution of an ammonium acetate buffer salt solution and methanol as a mobile phase A and acetonitrile as a mobile phase B; wherein the pH value of the ammonium acetate buffer salt solution is 4.9 to 5.2; and (3) gradient elution is adopted. The quality detection method disclosed by the invention can be used for the preparation process of the compound sodium picosulfate oral solution and the quality control of the final product, is good in specificity, good in separation degree, high in sensitivity and good in reproducibility, and has important significance for evaluating the advantages and disadvantages of synthesis and preparation processes, controlling the quality of the final product and detecting a stable sample.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

The invention belongs to the technical field of oral liquid, and provides DHA algae oil oral liquid and a preparation method thereof. The preparation method comprises the following steps: mixing sodium hexametaphosphate, disodium hydrogen phosphate, sodium caseinate, starch sodium octenylsuccinate and water, and refrigerating to obtain a water phase; mixing docosahexaenoic acid, caprylic capric triglyceride, essence and vitamin E oil to obtain an oil phase; adding the oil phase into the water phase, stirring at a high speed, and homogenizing the primary emulsion to obtain an embedded emulsion; and mixing the embedding emulsion, sucralose, sweet orange essence and water to obtain the DHA algae oil oral liquid. The DHA algal oil oral liquid forms a double-layer nano-emulsion structure, and the DHA algal oil nano-emulsion oral liquid with the double-layer structure has good thermal stability, freeze-thaw stability, salt, acid and alkali tolerance and long-term storage stability, and provides technical reference for development of DHA high-stability products and application of the DHA high-stability products in food processing.

Disclosed herein is a ready-to-use, non-aqueous oral solution of losartan. Also disclosed herein is a method of preparing a ready-to-use, non-aqueous oral solution of losartan and its method of use.

The invention relates to a method for determining the content of sorbitol and glycerol as auxiliary materials in a fudosteine oral solution, which has the advantages of high sensitivity, strong specificity, good accuracy and simple and rapid operation, can reduce the difficulty of preparation development, reduce the workload of prescription development, shorten the research and development time and further improve the BE passing rate, and has practical significance.

The application belongs to the technical field of drug dissolution and dispersion, and particularly relates to a bunazosin water-based solution preparation and a preparation method. The bunazosin water-based solution preparation provided by the application comprises the following components: bunazosin, gamma-cyclodextrin, lecithin, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, aspartame and water. The above components are mixed to be homogeneous to prepare an oral solution which is uniform, clear and can be stored for a long time. The scheme of the application further enriches the dosage form of bunazosin, improves the convenience of taking bunazosin, and is expected to help improve the oral bioavailability and absorption efficiency of bunazosin. The scheme of the application also provides a reference direction for the mechanism research on the dissolution and dispersion behavior of the insoluble bunazosin macromolecule in a water medium.